Highlights the phenomenon of 'stunned myocardium' following coronary reperfusion and recommends that clinical trials assess long-term rather than short-term changes in cardiac function.
Answers are grounded in this paper and cite their sources.
Early post-reperfusion function assessment may underestimate recovery; leaves open optimal long-term endpoints for reperfusion trials.
There has been recent interest in treating acute myocardial infarction with coronary reperfusion by fibrinolytic therapy. Experimental studies have shown that myocardial infarct size can be reduced by coronary reperfusion. However, return of cardiac function, high energy phosphate metabolism, and cardiac ultrastructure may be delayed within tissue which is salvaged by coronary reperfusion. This postischemic ventricular dysfunction is transient and has been termed the 'stunned myocardium' phenomenon. Although reperfused infarcts are hemorrhagic, the hemorrhage is confined well within tissue which is already necrotic and does not appear to exacerbate the extent of necrosis. Clinical trials designed to assess the benefits of reperfusion for the therapy of acute myocardial infarction should concentrate on long-term rather than short-term changes in cardiac function.
No takes yet. Share an insight, caveat, or question.
Kloner et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: